HBV Pre-S1 Polypeptide Therapy for NAFLD Insulin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) are challenging due to its association with insulin resistance, lipid metabolism disorders, and progression to severe conditions like cirrhosis and hepatocellular carcinoma, with limited effective therapeutic options.
Innovation Solution
The use of polypeptides derived from the pre-S1 region of HBV genotypes A, B, C, D, E, F, G, and H, specifically targeting the amino acid sequence 13-59 of HBV genotype C, which are administered to treat NAFLD, either alone or in combination with other therapeutic agents like antihyperlipidemic or antidiabetic drugs, to reduce liver fat, improve insulin resistance, and mitigate associated symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for NAFLD, then existing therapeutic options are limited, but treatment effectiveness is insufficient due to the complex pathogenesis involving insulin resistance and lipid metabolism disorders
Solution Approach 1:
The patent uses a polypeptide derived from HBV pre-S1 region as an intermediary substance that mediates the treatment of NAFLD. This polypeptide acts as a bridge to address the complex pathogenesis by simultaneously targeting insulin resistance and lipid metabolism disorders, which are the underlying mechanisms of NAFLD. The intermediary polypeptide provides a novel therapeutic approach that overcomes the limitations of conventional treatments.
2Reliability
If NAFLD progresses to severe conditions like cirrhosis and hepatocellular carcinoma, then disease severity increases, but treatment difficulty and prognosis worsen significantly
Solution Approach 1:
The patent applies preliminary action by using the HBV pre-S1 polypeptide to intervene in NAFLD at early stages before progression to severe conditions like cirrhosis and hepatocellular carcinoma. The polypeptide prevents the development of insulin resistance and lipid metabolism disorders that would otherwise lead to disease progression, thereby improving prognosis by acting beforehand rather than treating advanced disease.
3Reliability
If polypeptide treatment is administered to reduce liver fat and improve insulin resistance, then therapeutic benefit is achieved, but the specific mechanism involving HBV pre-S1 region needs to be validated
Solution Approach 1:
The patent employs feedback mechanisms to validate the therapeutic mechanism of the HBV pre-S1 polypeptide. By monitoring changes in liver fat content, insulin resistance markers, and other relevant parameters in response to polypeptide administration, the patent establishes a feedback loop that confirms the causal relationship between the polypeptide treatment and the observed therapeutic benefits, thereby validating the mechanism.
Data Source
AI summary
The disclosure relates to therapeutic medicaments for nonalcoholic fatty liver disease. Specifically, the disclosure relates to use of a polypeptide comprising an amino acid sequence derived from hepatitis B virus (HBV) or a pharmaceutical composition comprising the polypeptide in the manufacture of a medicament for treating or preventing nonalcoholic fatty liver disease.